Department of Neurology, University of Ulm, Oberer Eselsberg 45, Ulm, Germany.
Eur Neurol. 2011;65(3):164-9. doi: 10.1159/000324035. Epub 2011 Mar 3.
The patterns of Th1/Th2 cytokines in relapsing-remitting multiple sclerosis were analyzed to evaluate their relevance as biomarkers of therapy response to glatiramer acetate (GA). Serum interferon-γ (IFN-γ), osteopontin and interleukin (IL)-2, IL-4, and IL-10 were measured in 19 relapsing-remitting multiple sclerosis patients treated with GA in a prospective study over 3 years. The quotient (IL-2 + IFN-γ)/(IL-4 + IL-10) was elevated in patients with relapses as compared to relapse-free patients after 12 (p = 0.04), 24 (p = 0.02) and 36 months (p = 0.04). Our study indicates that specific patterns of Th1/Th2 cytokines predict the response to GA therapy.
分析复发缓解型多发性硬化症患者的 Th1/Th2 细胞因子模式，以评估其作为对醋酸格拉替雷治疗反应的生物标志物的相关性。在一项为期 3 年的前瞻性研究中，对 19 例接受 GA 治疗的复发缓解型多发性硬化症患者进行了血清干扰素-γ (IFN-γ)、骨桥蛋白和白细胞介素 (IL)-2、IL-4 和 IL-10 的测定。与缓解后无复发的患者相比，复发患者的 IL-2 + IFN-γ)/(IL-4 + IL-10) 比值在 12 (p = 0.04)、24 (p = 0.02) 和 36 个月 (p = 0.04) 时升高。我们的研究表明，Th1/Th2 细胞因子的特定模式可预测对 GA 治疗的反应。
